A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

Launched by SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. · Apr 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SSS59 for patients with advanced malignant tumors, which are serious types of cancer that have spread or come back after treatment. The trial is in its early phase, meaning researchers are primarily looking to see if the treatment is safe, how the body processes it, and if it shows any signs of fighting the cancer on its own. This study is not yet recruiting participants, but when it does, it will welcome both men and women between the ages of 18 and 100 who have a specific type of cancer that can be confirmed through medical tests.

To be eligible for this trial, participants must have a type of advanced cancer that has been confirmed by a doctor, be in generally good health with an expected survival of more than three months, and have the ability to understand and sign a consent form. However, there are some restrictions; for example, individuals with serious side effects from previous cancer treatments, those who are pregnant or breastfeeding, and patients with certain brain tumors cannot participate. If someone joins the study, they can expect close monitoring by healthcare professionals to ensure their safety while receiving SSS59. This trial represents an important step in exploring new treatment options for patients with challenging cancer diagnoses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically and/or cytologically documented local advanced or recurrent or metastatic malignancies.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• • Expected survival \>3 months.
• • Signed informed consent form.
• • Must have adequate organ function.
• Exclusion Criteria:
• • Any remaining AEs \> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.
• • Pregnant or nursing women or women/men who are ready to give birth.
• • symptomatic central nervous system metastasis.
• • Allergy to other antibody drugs or any excipients in the study drugs.
• • Underwent major surgery within 4 weeks prior to first dosing.
• • The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.
• • The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.